Novo Nordisk A/S (NYSE:NVO) Hits New 12-Month Low on Analyst Downgrade

Novo Nordisk A/S (NYSE:NVO)’s stock price hit a new 52-week low during trading on Monday after Deutsche Bank Aktiengesellschaft downgraded the stock from a buy rating to a hold rating. The stock traded as low as $40.01 and last traded at $41.0070, with a volume of 5989976 shares. The stock had previously closed at $47.42.

Several other research firms have also issued reports on NVO. HSBC restated a “hold” rating and issued a $54.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, February 5th. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. The Goldman Sachs Group restated a “buy” rating on shares of Novo Nordisk A/S in a report on Thursday, January 22nd. Finally, Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Seven analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S has an average rating of “Hold” and an average target price of $56.07.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CagriSema produced meaningful weight loss (reported ~23% in the REDEFINE‑4 open‑label trial), which could still support potential labeling, combination uses, or niche commercial opportunities even though the primary endpoint versus tirzepatide was not met. Novo Nordisk A/S: CagriSema demonstrated 23% weight loss…
• Positive Sentiment: Novo Nordisk remains a cash‑generative leader in diabetes and obesity (Wegovy/Ozempic franchise) with recent quarterly beats and a strong margin profile, which provides balance sheet flexibility to fund R&D and defend market share. 2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $200
• Neutral Sentiment: Some strategists still include NVO in thematic or “vanity” trade lists, reflecting investor interest in large, well‑known GLP‑1 plays despite volatility; this may support episodic buying interest. 2 ‘vanity’ stock picks & 1 crypto play this strategist loves
• Negative Sentiment: Major headline: CagriSema did not achieve non‑inferiority to Lilly’s tirzepatide on weight loss at 84 weeks, triggering a sharp selloff as investors reassess Novo’s competitive outlook in obesity. Novo Nordisk’s next obesity drug falls short of Lilly rival, wiping billions off its market value
• Negative Sentiment: Multiple major outlets report the trial setback and market reaction, noting the plunge erased prior Wegovy-era gains and increases the risk that Lilly will capture a larger share of the obesity market. Novo Nordisk slump wipes out last Wegovy-era gains after trial setback
• Negative Sentiment: Coverage from CNBC and the WSJ highlights the magnitude of the market move and frames this as a key turning point in the GLP‑1 competitive race, which could pressure short‑ and medium‑term growth expectations. Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly’s in trial

Hedge Funds Weigh In On Novo Nordisk A/S

Hedge funds have recently bought and sold shares of the company. Revolve Wealth Partners LLC increased its position in Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 21.0% during the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after buying an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC lifted its stake in shares of Novo Nordisk A/S by 18.2% in the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock valued at $712,000 after acquiring an additional 1,587 shares during the last quarter. 180 Wealth Advisors LLC lifted its stake in shares of Novo Nordisk A/S by 9.5% in the 2nd quarter. 180 Wealth Advisors LLC now owns 5,492 shares of the company’s stock valued at $379,000 after acquiring an additional 478 shares during the last quarter. Finally, Focus Partners Advisor Solutions LLC boosted its holdings in shares of Novo Nordisk A/S by 16.3% during the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 7,318 shares of the company’s stock valued at $504,000 after acquiring an additional 1,024 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Price Performance

The business has a 50-day moving average of $53.77 and a two-hundred day moving average of $53.30. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The firm has a market cap of $179.94 billion, a P/E ratio of 11.61 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The company had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently declared a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be paid a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 23.63%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.